Hashimoto's thyroiditis (autoimmune thyroid)
The most common cause of hypothyroidism in iodine-sufficient populations — autoimmune destruction of thyroid follicular cells driven by TPO and thyroglobulin antibodies. Affects ~5% of adults, women 7-10× more than men.
What changes during this transition
Hashimoto's is autoimmune disease first and hypothyroidism second — that ordering shapes how every peptide question gets framed. Standard-of-care is levothyroxine for biochemical hypothyroidism (treats the hormonal consequence, not the autoimmunity); T3 supplementation is a real but controversial conversation with endocrinology when free T3 stays low on adequate T4; selenium supplementation (200 μg/day) has RCT meta-analytic evidence (Toulis 2010 and successors) for TPO antibody reduction without consistent free T4 or symptomatic improvement; vitamin D status, B12 status, ferritin, and selenium status are the established repletion conversations. The autoimmune axis is Th1/Th17-polarized with regulatory T-cell insufficiency — which is exactly why several 'immune-boosting' peptides marketed to fatigue-and-brain-fog populations are directionally wrong for this disease. The peptides surfaced here are the ones with either confirmed-deficiency repletion cases (B12 in the pernicious-anemia / atrophic-gastritis subset that overlaps heavily with Hashimoto's) or anxiety-component cases (selank for the anxious-hypothyroid mood presentation). The Th1-augmenting immune-modulators (thymosin alpha-1, LL-37) are kept as substrate ONLY because their mechanism is mechanism-aligned with the disease — community use is real, the wrong-direction concern needs to be on the record. Graves' overlap is editorially adjacent: same autoimmune-thyroid family, opposite hormonal direction (hyperthyroid, TRAb/TSI-driven); the immune-modulator wrong-direction concern applies equally.
Important caveat
Hashimoto's deserves endocrinology coordination — peptides don't replace levothyroxine, the T3 conversation, or antibody/hormonal monitoring. Rule out standard repletion conversations FIRST: serum B12 + MMA + homocysteine (pernicious anemia / atrophic-gastritis overlap is common), 25-hydroxy vitamin D, ferritin, and selenium status. CRITICAL: Th1-augmenting immune-modulators (thymosin alpha-1, LL-37) are mechanistically wrong-direction for Th1/Th17-polarized autoimmune thyroid disease — community 'immune support' framing doesn't engage with this. Pregnancy planning with Hashimoto's needs preconception TSH optimization (target <2.5 mIU/L per ATA 2017). Graves' disease (autoimmune hyperthyroid mirror) shares the immune-modulator wrong-direction concern.
Peptides editorially relevant to hashimoto's thyroiditis (autoimmune thyroid)
2 peptides from the library — each evidence-tiered honestly.
- B12 (Methylcobalamin)Tier 1
Vitamin (methylcobalamin)
Vitamin B12 in the methyl form. Solid evidence for treating documented deficiency and pernicious anemia. The wellness-clinic 'energy injection' market for non-deficient adults has no clinical-trial support.
- SelankTier 3
Synthetic tuftsin analog (heptapeptide)
Russian-developed anxiolytic/nootropic peptide. Most clinical data is in Russian and methodologically thin by Western standards. Tier 3. Routes include intranasal — a natural pair with Juno's nasal-spray prep guide.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.